This article was originally published in Start Up
Cogs aims to develop a diagnostic kit that will enable detection of breast and ovarian cancer, when the disease is still at a very early stage of develoment. No firm has yet achieved such a feat, which is one reason why a woman dies every 11 minutes from one of these two cancers.
You may also be interested in...
New hunters of diagnostic biomarkers hope to improve cancer diagnosis. They envision biomarkers that will allow more accurate disease-stage monitoring, more effective choice of therapy and, ultimately, the development of therapies themselves. Despite the plethora of new technologies, tools, and genomic data, however, cancer-specific markers have provent obe difficult beasts to catch.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker